Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

This case report describes how changing treatment from adalimumab to guselkumab successfully controlled both pustulotic arthro-osteitis and paradoxical skin reactions in a patient with palmoplantar pustulosis.

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.

This review suggests that IL-23 inhibitors may be effective for various non-psoriatic inflammatory skin conditions, but emphasizes the need for further large-scale trials to confirm their efficacy and safety.